A citation-based method for searching scientific literature

Lily R Aleksandrova, Anthony G Phillips. Trends Pharmacol Sci 2021
Times Cited: 20







List of co-cited articles
350 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial.
Alan K Davis, Frederick S Barrett, Darrick G May, Mary P Cosimano, Nathan D Sepeda, Matthew W Johnson, Patrick H Finan, Roland R Griffiths. JAMA Psychiatry 2021
233
60

Psychedelics Promote Structural and Functional Neural Plasticity.
Calvin Ly, Alexandra C Greb, Lindsay P Cameron, Jonathan M Wong, Eden V Barragan, Paige C Wilson, Kyle F Burbach, Sina Soltanzadeh Zarandi, Alexander Sood, Michael R Paddy,[...]. Cell Rep 2018
292
60

Psychedelics.
David E Nichols. Pharmacol Rev 2016
517
55

Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial.
Roland R Griffiths, Matthew W Johnson, Michael A Carducci, Annie Umbricht, William A Richards, Brian D Richards, Mary P Cosimano, Margaret A Klinedinst. J Psychopharmacol 2016
612
55

Trial of Psilocybin versus Escitalopram for Depression.
Robin Carhart-Harris, Bruna Giribaldi, Rosalind Watts, Michelle Baker-Jones, Ashleigh Murphy-Beiner, Roberta Murphy, Jonny Martell, Allan Blemings, David Erritzoe, David J Nutt. N Engl J Med 2021
228
50

Psilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in vivo.
Ling-Xiao Shao, Clara Liao, Ian Gregg, Pasha A Davoudian, Neil K Savalia, Kristina Delagarza, Alex C Kwan. Neuron 2021
62
50

Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial.
Stephen Ross, Anthony Bossis, Jeffrey Guss, Gabrielle Agin-Liebes, Tara Malone, Barry Cohen, Sarah E Mennenga, Alexander Belser, Krystallia Kalliontzi, James Babb,[...]. J Psychopharmacol 2016
507
45

Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action.
F X Vollenweider, M F Vollenweider-Scherpenhuyzen, A Bäbler, H Vogel, D Hell. Neuroreport 1998
512
40

Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study.
Robin L Carhart-Harris, Mark Bolstridge, James Rucker, Camilla M J Day, David Erritzoe, Mendel Kaelen, Michael Bloomfield, James A Rickard, Ben Forbes, Amanda Feilding,[...]. Lancet Psychiatry 2016
528
40


The Subjective Effects of Psychedelics Are Necessary for Their Enduring Therapeutic Effects.
David B Yaden, Roland R Griffiths. ACS Pharmacol Transl Sci 2020
75
35

Harnessing psilocybin: antidepressant-like behavioral and synaptic actions of psilocybin are independent of 5-HT2R activation in mice.
Natalie Hesselgrave, Timothy A Troppoli, Andreas B Wulff, Anthony B Cole, Scott M Thompson. Proc Natl Acad Sci U S A 2021
55
35

Transient Stimulation with Psychoplastogens Is Sufficient to Initiate Neuronal Growth.
Calvin Ly, Alexandra C Greb, Maxemiliano V Vargas, Whitney C Duim, Ana Cristina G Grodzki, Pamela J Lein, David E Olson. ACS Pharmacol Transl Sci 2020
24
35

MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study.
Jennifer M Mitchell, Michael Bogenschutz, Alia Lilienstein, Charlotte Harrison, Sarah Kleiman, Kelly Parker-Guilbert, Marcela Ot'alora G, Wael Garas, Casey Paleos, Ingmar Gorman,[...]. Nat Med 2021
155
35

Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study.
Michael P Bogenschutz, Alyssa A Forcehimes, Jessica A Pommy, Claire E Wilcox, P C R Barbosa, Rick J Strassman. J Psychopharmacol 2015
413
35


A Dendrite-Focused Framework for Understanding the Actions of Ketamine and Psychedelics.
Neil K Savalia, Ling-Xiao Shao, Alex C Kwan. Trends Neurosci 2021
29
30

Emotions and brain function are altered up to one month after a single high dose of psilocybin.
Frederick S Barrett, Manoj K Doss, Nathan D Sepeda, James J Pekar, Roland R Griffiths. Sci Rep 2020
83
30

A non-hallucinogenic psychedelic analogue with therapeutic potential.
Lindsay P Cameron, Robert J Tombari, Ju Lu, Alexander J Pell, Zefan Q Hurley, Yann Ehinger, Maxemiliano V Vargas, Matthew N McCarroll, Jack C Taylor, Douglas Myers-Turnbull,[...]. Nature 2021
77
30



Psychedelic drugs: neurobiology and potential for treatment of psychiatric disorders.
Franz X Vollenweider, Katrin H Preller. Nat Rev Neurosci 2020
107
30

Psilocybin therapy increases cognitive and neural flexibility in patients with major depressive disorder.
Manoj K Doss, Michal Považan, Monica D Rosenberg, Nathan D Sepeda, Alan K Davis, Patrick H Finan, Gwenn S Smith, James J Pekar, Peter B Barker, Roland R Griffiths,[...]. Transl Psychiatry 2021
26
30


Catalysts for change: the cellular neurobiology of psychedelics.
Matthew I Banks, Zarmeen Zahid, Nathan T Jones, Ziyad W Sultan, Cody J Wenthur. Mol Biol Cell 2021
9
55

Effects of psilocybin on hippocampal neurogenesis and extinction of trace fear conditioning.
Briony J Catlow, Shijie Song, Daniel A Paredes, Cheryl L Kirstein, Juan Sanchez-Ramos. Exp Brain Res 2013
108
25

Lysergic acid diethylamide and [-]-2,5-dimethoxy-4-methylamphetamine increase extracellular glutamate in rat prefrontal cortex.
John W Muschamp, Meredith J Regina, Elaine M Hull, Jerrold C Winter, Richard A Rabin. Brain Res 2004
64
25

Psychedelics as Medicines: An Emerging New Paradigm.
D E Nichols, M W Johnson, C D Nichols. Clin Pharmacol Ther 2017
123
25

Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants.
Ronald S Duman, George K Aghajanian, Gerard Sanacora, John H Krystal. Nat Med 2016
761
25

Psychedelic Drugs in Biomedicine.
Evan J Kyzar, Charles D Nichols, Raul R Gainetdinov, David E Nichols, Allan V Kalueff. Trends Pharmacol Sci 2017
77
25

Changes in global and thalamic brain connectivity in LSD-induced altered states of consciousness are attributable to the 5-HT2A receptor.
Katrin H Preller, Joshua B Burt, Jie Lisa Ji, Charles H Schleifer, Brendan D Adkinson, Philipp Stämpfli, Erich Seifritz, Grega Repovs, John H Krystal, John D Murray,[...]. Elife 2018
122
25

Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanisms.
Antonio Inserra, Danilo De Gregorio, Gabriella Gobbi. Pharmacol Rev 2021
46
25

Hallucinogens.
David E Nichols. Pharmacol Ther 2004
716
25


Acute dose-dependent effects of lysergic acid diethylamide in a double-blind placebo-controlled study in healthy subjects.
Friederike Holze, Patrick Vizeli, Laura Ley, Felix Müller, Patrick Dolder, Melanie Stocker, Urs Duthaler, Nimmy Varghese, Anne Eckert, Stefan Borgwardt,[...]. Neuropsychopharmacology 2021
62
25

Psilocybin with psychological support for treatment-resistant depression: six-month follow-up.
R L Carhart-Harris, M Bolstridge, C M J Day, J Rucker, R Watts, D E Erritzoe, M Kaelen, B Giribaldi, M Bloomfield, S Pilling,[...]. Psychopharmacology (Berl) 2018
277
25

Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels.
Martin K Madsen, Patrick M Fisher, Daniel Burmester, Agnete Dyssegaard, Dea S Stenbæk, Sara Kristiansen, Sys S Johansen, Sczabolz Lehel, Kristian Linnet, Claus Svarer,[...]. Neuropsychopharmacology 2019
121
25

Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function.
Matthew W Johnson, Peter S Hendricks, Frederick S Barrett, Roland R Griffiths. Pharmacol Ther 2019
126
25

The Fabric of Meaning and Subjective Effects in LSD-Induced States Depend on Serotonin 2A Receptor Activation.
Katrin H Preller, Marcus Herdener, Thomas Pokorny, Amanda Planzer, Rainer Kraehenmann, Philipp Stämpfli, Matthias E Liechti, Erich Seifritz, Franz X Vollenweider. Curr Biol 2017
173
25

Acute Effects of Lysergic Acid Diethylamide in Healthy Subjects.
Yasmin Schmid, Florian Enzler, Peter Gasser, Eric Grouzmann, Katrin H Preller, Franz X Vollenweider, Rudolf Brenneisen, Felix Müller, Stefan Borgwardt, Matthias E Liechti. Biol Psychiatry 2015
210
25

Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences.
Theresa M Carbonaro, Matthew P Bradstreet, Frederick S Barrett, Katherine A MacLean, Robert Jesse, Matthew W Johnson, Roland R Griffiths. J Psychopharmacol 2016
143
25

An analog of psychedelics restores functional neural circuits disrupted by unpredictable stress.
Ju Lu, Michelle Tjia, Brian Mullen, Bing Cao, Kacper Lukasiewicz, Sajita Shah-Morales, Sydney Weiser, Lindsay P Cameron, David E Olson, Lu Chen,[...]. Mol Psychiatry 2021
17
23

Antidepressant effects of ketamine in depressed patients.
R M Berman, A Cappiello, A Anand, D A Oren, G R Heninger, D S Charney, J H Krystal. Biol Psychiatry 2000
20

Hallucinogens recruit specific cortical 5-HT(2A) receptor-mediated signaling pathways to affect behavior.
Javier González-Maeso, Noelia V Weisstaub, Mingming Zhou, Pokman Chan, Lidija Ivic, Rosalind Ang, Alena Lira, Maria Bradley-Moore, Yongchao Ge, Qiang Zhou,[...]. Neuron 2007
487
20

The neurobiology of psychedelic drugs: implications for the treatment of mood disorders.
Franz X Vollenweider, Michael Kometer. Nat Rev Neurosci 2010
329
20

Prolonged epigenomic and synaptic plasticity alterations following single exposure to a psychedelic in mice.
Mario de la Fuente Revenga, Bohan Zhu, Christopher A Guevara, Lynette B Naler, Justin M Saunders, Zirui Zhou, Rudy Toneatti, Salvador Sierra, Jennifer T Wolstenholme, Patrick M Beardsley,[...]. Cell Rep 2021
31
20

Modulation of Serum Brain-Derived Neurotrophic Factor by a Single Dose of Ayahuasca: Observation From a Randomized Controlled Trial.
Raíssa Nóbrega de Almeida, Ana Cecília de Menezes Galvão, Flávia Santos da Silva, Erick Allan Dos Santos Silva, Fernanda Palhano-Fontes, João Paulo Maia-de-Oliveira, Lobão-Soares Barros de Araújo, Bruno Lobão-Soares, Nicole Leite Galvão-Coelho. Front Psychol 2019
64
20

Lysergic acid diethylamide (LSD) promotes social behavior through mTORC1 in the excitatory neurotransmission.
Danilo De Gregorio, Jelena Popic, Justine P Enns, Antonio Inserra, Agnieszka Skalecka, Athanasios Markopoulos, Luca Posa, Martha Lopez-Canul, He Qianzi, Christopher K Lafferty,[...]. Proc Natl Acad Sci U S A 2021
23
20

A Single Dose of Psilocybin Increases Synaptic Density and Decreases 5-HT2A Receptor Density in the Pig Brain.
Nakul Ravi Raval, Annette Johansen, Lene Lundgaard Donovan, Nídia Fernandez Ros, Brice Ozenne, Hanne Demant Hansen, Gitte Moos Knudsen. Int J Mol Sci 2021
39
20

Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer.
Charles S Grob, Alicia L Danforth, Gurpreet S Chopra, Marycie Hagerty, Charles R McKay, Adam L Halberstadt, George R Greer. Arch Gen Psychiatry 2011
471
20


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.